MIF and psoriasis: Given that the levels of oxMIF within total MIF were significantly increased in the plasma of patients with different inflammatory diseases (sepsis, psoriasis, asthma, ulcerative colitis, Crohn’s disease, and systemic lupus erythematosus) versus control groups [23], oxMIF has been proposed as the “bad MIF”, which is, however, speculative.